US pharma bets big on China to snap up potential blockbuster drugs

U.S. drugmakers are increasingly licensing drug candidates from Chinese companies, with 14 deals worth a potential $18.3 billion signed in the first half of the year, compared to only two in the same period last year, as they seek to replenish pipelines ahead of significant patent expirations; these deals offer access to potentially high-quality assets at lower upfront costs, exemplified by Pfizer's $1.25 billion upfront payment for a cancer drug and Regeneron's $80 million deal for an obesity drug, reflecting China's growing share of global drug development and a strategic shift towards licensing over traditional M&A.

Analysis

U.S. drugmakers are significantly accelerating the licensing of potential new medicines from China-based companies, driven by the strategic imperative to replenish pipelines ahead of an estimated $200 billion worth of drugs losing patent protection by the end of the decade. Data from GlobalData indicates a substantial increase, with 14 deals potentially valued at $18.3 billion signed in the first half of the current year, a stark contrast to only two such deals in the comparable period last year. This trend is underpinned by access to high-quality assets at more favorable costs; Mizuho analyst Graig Suvannavejh highlights that U.S. firms are finding 'very high-quality assets coming out of China and at prices that are much more affordable.' Illustrating this, GlobalData reports that the total cost of licensing agreements over the past five years averaged $31.3 billion in China compared to $84.8 billion in the U.S., with upfront payments for Chinese assets sometimes as low as $80 million. China's role in global drug development has expanded to nearly 30%, while the U.S. share of global R&D has slightly decreased to about 48%. Prominent examples include Pfizer's $1.25 billion upfront payment (for a deal potentially worth up to $6 billion) for a cancer drug from China's 3SBio, and Regeneron's $80 million upfront payment (in a potential $2 billion deal) for an experimental obesity drug from Hansoh Pharmaceuticals. Furthermore, Nuvation Bio's acquisition of AnHeart Therapeutics provided access to the China-developed cancer drug taletrectinib, which recently received U.S. approval. This surge in licensing, particularly for novel treatments such as targeted cancer therapies and first-in-class medicines, is occurring despite U.S.-China geopolitical tensions and a 20% decline in traditional M&A, as intellectual property licensing is currently viewed by some experts like Stifel's Tim Opler as distinct from goods subject to tariffs. Industry experts, such as Brian Gleason of Raymond James, project that licensing deals involving Chinese assets could rise to represent 40% to 50% of large pharmaceutical companies' in-licensing activities, signaling quicker and more cost-efficient access to innovation.

Key Decisions for Investors

• Investors should evaluate U.S. pharmaceutical companies like Pfizer (PFE), Regeneron (REGN), and Nuvation Bio (NUVB) based on their strategic execution of licensing deals with Chinese entities, as successful integration of these lower-cost, high-potential assets can significantly bolster drug pipelines and future revenue streams.
• It is prudent to monitor the clinical development progress and regulatory approvals of drugs licensed from China, such as Nuvation Bio's taletrectinib, as these outcomes are critical indicators of the value derived from such partnerships and the viability of this sourcing strategy.
• Consider opportunities in innovative Chinese biotech firms poised to benefit from this trend, as they are increasingly recognized as sources of valuable drug candidates for global pharmaceutical companies.
• Investors should remain vigilant regarding potential shifts in U.S. trade policy or specific regulations targeting pharmaceutical collaborations with China, as geopolitical risks could impact the viability and profitability of these licensing agreements, despite current interpretations that exclude intellectual property from tariffs.